| Revision as of 09:39, 4 September 2017 editInternetArchiveBot (talk | contribs)Bots, Pending changes reviewers5,383,899 edits Rescuing 1 sources and tagging 0 as dead. #IABot (v1.5)← Previous edit | Revision as of 01:44, 18 September 2017 edit undoInternetArchiveBot (talk | contribs)Bots, Pending changes reviewers5,383,899 edits Rescuing 2 sources and tagging 0 as dead. #IABot (v1.5.2)Next edit → | ||
| Line 27: | Line 27: | ||
| ==Career== | ==Career== | ||
| Vasella held a number of medical positions in Switzerland before being hired in 1988 by Sandoz Pharmaceutical Corporation, the former U.S. subsidiary of Swiss pharmaceutical company, ]. He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd., and named a member of the Group Executive Committee.<ref name=10BBC /><ref name=9WC>{{cite web |title=Curriculum Vitae: Dr. Daniel Vasella |url=http://www.novartis.com/downloads/about-novartis/people/board-of-directors/Biography_Daniel_Vasella_DE.pdf |work=WebCite |accessdate=15 May 2013 |deadurl=yes |archiveurl= |
Vasella held a number of medical positions in Switzerland before being hired in 1988 by Sandoz Pharmaceutical Corporation, the former U.S. subsidiary of Swiss pharmaceutical company, ]. He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd., and named a member of the Group Executive Committee.<ref name=10BBC /><ref name=9WC>{{cite web |title=Curriculum Vitae: Dr. Daniel Vasella |url=http://www.novartis.com/downloads/about-novartis/people/board-of-directors/Biography_Daniel_Vasella_DE.pdf |work=WebCite |accessdate=15 May 2013 |deadurl=yes |archiveurl=https://www.webcitation.org/6DtlcoRaH?url=http://www.novartis.com/downloads/about-novartis/people/board-of-directors/Biography_Daniel_Vasella_DE.pdf |archivedate=January 24, 2013 |df= }}</ref> | ||
| Vasella helped to orchestrate the 1996 merger between Sandoz and ], another Swiss pharmaceutical company.<ref name=10BBC /> The two companies combined to form ]. Vasella was appointed CEO of the combined entity and a member of the Board of Directors. In 1999, he was named Chairman of the Board of Directors.<ref name=10BBC /> | Vasella helped to orchestrate the 1996 merger between Sandoz and ], another Swiss pharmaceutical company.<ref name=10BBC /> The two companies combined to form ]. Vasella was appointed CEO of the combined entity and a member of the Board of Directors. In 1999, he was named Chairman of the Board of Directors.<ref name=10BBC /> | ||
| Line 33: | Line 33: | ||
| In January 2010, Vasella decided to step down as CEO. He was replaced by his hand-picked successor, ], the Division Head of Novartis Pharmaceuticals at the time. | In January 2010, Vasella decided to step down as CEO. He was replaced by his hand-picked successor, ], the Division Head of Novartis Pharmaceuticals at the time. | ||
| In January 2013, Novartis announced that Vasella would be retiring as Chairman of the Board of Directors in February 2013.<ref>'']'': ""</ref> Vasella was named an honorary chairman, to be succeeded by Jörg Reinhard in August 2013.<ref>''Pharmaceutical Market Europe'': ""</ref> According to the Ethos foundation Vasella earned from 2002 until 2012 312 Mio CHF from Novartis, and for the years before they estimated it to 60 Mio CHF, a total of 421 Mio CHF in 2013. That he should get 72 Mio CHF for a noncompetition clause at the end made him a public figure during the campaign for the ].<ref>, Aargauer Zeitung, 2013-02-22.</ref><ref>, NZZ, 2013-02-16.</ref><ref name=bilanz022013>, Bilanz, 2013-02-19.</ref> | In January 2013, Novartis announced that Vasella would be retiring as Chairman of the Board of Directors in February 2013.<ref>'']'': " {{webarchive|url=https://web.archive.org/web/20130127092811/http://www.businessweek.com/news/2013-01-23/novartis-s-vasella-to-resign-bayer-s-reinhardt-returns |date=2013-01-27 }}"</ref> Vasella was named an honorary chairman, to be succeeded by Jörg Reinhard in August 2013.<ref>''Pharmaceutical Market Europe'': ""</ref> According to the Ethos foundation Vasella earned from 2002 until 2012 312 Mio CHF from Novartis, and for the years before they estimated it to 60 Mio CHF, a total of 421 Mio CHF in 2013. That he should get 72 Mio CHF for a noncompetition clause at the end made him a public figure during the campaign for the ].<ref>, Aargauer Zeitung, 2013-02-22.</ref><ref>, NZZ, 2013-02-16.</ref><ref name=bilanz022013>, Bilanz, 2013-02-19.</ref> | ||
| ==Writing== | ==Writing== | ||
Revision as of 01:44, 18 September 2017
| Daniel Vasella | |
|---|---|
 Vasella at the World Economic Forum in Davos, 2013 | |
| Born | Daniel Lucius Vasella (1953-08-15) August 15, 1953 (age 71) Fribourg, Switzerland |
| Alma mater | University of Bern (MD) Harvard Business School (PMD) |
| Occupation(s) | Unemployed, consulting for different companies, Director of Boards |
| Spouse | Anne-Laurence |
| Children | 3 |
Daniel Lucius Vasella, M.D. (born 15 August 1953) is a medical doctor, author, and executive who served as CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. During his tenure the Novartis shares declined 10%, below the industry.
In November 2014, Vasella was elected as a member of the Board of Directors at XBiotech, Inc., a Biopharmaceutical Company located in Austin, Texas, that focuses on the discovery and commercialization of a next generation of therapeutic antibodies which harness a human's natural immunity to fight disease. Vasella is an honorary member of the American Academy of Arts and Sciences. In 2004, Time magazine named him one of the world’s 100 most influential people, and he was chosen as the Most Influential European Business Leader of the Last 25 Years by the readers of the Financial Times. He is a former member of the Steering Committee of the Bilderberg Group.
Early life and education
Vasella was born in Fribourg, Switzerland, in 1953. His father was a history professor at the local university, and his mother was a housewife. His desire to become a doctor began during his childhood, which was marked by several tragedies. At eight years old, he contracted TB and meningitis and spent nearly a year in hospitals. When Vasella was 13 years old, his father died from complications of surgery.
Vasella obtained his M.D. in 1980 from the University of Bern in Switzerland. He completed his residency at the University Hospital in Bern and the city hospital in Zurich, before returning to Bern as chief resident. In 1988, he changed career paths, working in the United States as a pharmaceutical sales representative and in market research. In 1989, he completed the Program for Management Development at Harvard Business School. Vasella was awarded an honorary doctorate for medicine by the University of Basel in 2002.
Career
Vasella held a number of medical positions in Switzerland before being hired in 1988 by Sandoz Pharmaceutical Corporation, the former U.S. subsidiary of Swiss pharmaceutical company, Sandoz. He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd., and named a member of the Group Executive Committee.
Vasella helped to orchestrate the 1996 merger between Sandoz and Ciba-Geigy, another Swiss pharmaceutical company. The two companies combined to form Novartis AG. Vasella was appointed CEO of the combined entity and a member of the Board of Directors. In 1999, he was named Chairman of the Board of Directors.
In January 2010, Vasella decided to step down as CEO. He was replaced by his hand-picked successor, Joseph Jimenez, the Division Head of Novartis Pharmaceuticals at the time.
In January 2013, Novartis announced that Vasella would be retiring as Chairman of the Board of Directors in February 2013. Vasella was named an honorary chairman, to be succeeded by Jörg Reinhard in August 2013. According to the Ethos foundation Vasella earned from 2002 until 2012 312 Mio CHF from Novartis, and for the years before they estimated it to 60 Mio CHF, a total of 421 Mio CHF in 2013. That he should get 72 Mio CHF for a noncompetition clause at the end made him a public figure during the campaign for the Swiss referendum "against rip-off salaries".
Writing
Vasella authored Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History (2003), a book about the discovery and development of the breakthrough cancer drug Gleevec. The book was co-written with Robert Slater.
Personal life
Vasella met Anne-Laurence Moret, the niece of former Sandoz CFO, CEO, and chairman Marc Moret, in 1973, and they were married in 1978. Vasella and his wife have two grown sons and a daughter. His older brother, Andrea Vasella, was a professor at the ETH Zurich. Vasella is a patron of the arts and enjoys skiing and spending time outdoors.
Awards and recognition
Vasella has received numerous awards for his humanitarian efforts, corporate philanthropy work, and his leadership in the Pharmaceutical industry. They include:
- 2003: Harvard Alumnus Award
- 2004: Most Influential European Business Leader of the Last 25 Years by the readers of Financial Times
- 2004: Time magazine: One of the Top 100 Most Influential Personalities
- 2004: The Cancer Research Institute’s Oliver R. Grace Award (for Distinguished Service in Advancing Cancer Research)
- University of Marburg’s Karl Winnacker Preis 2007
- Elected to the American Academy of Arts and Sciences 2008
- GILD Award for Leadership: Warren Bennis Award for Excellence in Leadership 2010
External links
- December 2009 USA Today Q&A with Dan Vasella
- Business Week Cover Story, "Novartis: Radically Remaking Its Drug Business"
- Indian patent laws discriminate against the innovation-focused pharmaceutical industry, Mint of India, 10 May 2007
- Drug Lord, Time Magazine, 13 Nov 2007
- Daniel Vasella biography, Forbes.com
- Dr. Daniel Vasella, medizin-kunst.de, 15 Nov 2014
References
- The Pharmaceutical Horizon Beckons, The New York Times, 13 August 2005
- ^ Madslien, Jorn. "Profile: Novartis chief Daniel Vasella". BBC News. Retrieved 15 May 2013.
- Keiner verdiente mehr., Bilanz, 02/2013
- ^ Vasella: Das Ende der Macht, Bilanz, 2013-02-19.
- ^ "American Express Company Elects Dr. Daniel Vasella to Board of Directors". American Express. Retrieved 15 May 2013.
- ^ The 2004 Time 100 : Daniel Vasella, Time
- "Former Steering Committee Members". bilderbergmeetings.org. Bilderberg Group. Archived from the original on 2014-02-02. Retrieved 2014-02-08.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ 2003 Alumni Achievement Award for D. Vasella
- ^ "An interview with Daniel Vasella". McKinsey & Company. Retrieved 15 May 2013.
- "Curriculum Vitae: Dr. Daniel Vasella" (PDF). WebCite. Archived from the original (PDF) on January 24, 2013. Retrieved 15 May 2013.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - Businessweek: "Vasella Quitting Wins Cheers From Novartis’s Investors Archived 2013-01-27 at the Wayback Machine"
- Pharmaceutical Market Europe: "Bayer’s Jörg Reinhardt to replace Daniel Vasella as Novartis chair"
- Daniel Vasella hat bei Novartis 421 Millionen Franken verdient, Aargauer Zeitung, 2013-02-22.
- Vasella verhilft Abzocker-Initiative womöglich zum Sieg, NZZ, 2013-02-16.
- Vasella Slater, Daniel Robert. "Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History". Amazon. Retrieved 15 May 2013.
- ^ "Blick für die Frau". Die Weltwoche. Retrieved 15 May 2013.
- "Daniel Vasella". Bloomberg Businessweek. Retrieved 15 May 2013.
- "Alumni Achievement Awards: Daniel L. Vasella, M.D." Harvard Business School. Retrieved 15 May 2013.
- Cancer Research Institute, Oliver R. Grace Award.
- "Verleihung des Karl-Winnacker-Preises 2007 an Dr. Daniel Vasella". Philipps-Universität, Marburg. Retrieved 15 May 2013.
